Scarica l'app Stockscreener
31.94
4.24%
1.30
Dopo l'orario di chiusura:
31.95
0.010
+0.03%
Precedente Chiudi:
$30.64
Aprire:
$31
Volume 24 ore:
765.31K
Relative Volume:
0.67
Capitalizzazione di mercato:
$3.43B
Reddito:
-
Utile/perdita netta:
$-167.80M
Rapporto P/E:
-19.57
EPS:
-1.6323
Flusso di cassa netto:
$-144.07M
1 W Prestazione:
+7.58%
1M Prestazione:
+6.04%
6M Prestazione:
+114.58%
1 anno Prestazione:
+40.09%
Intervallo 1D:
$30.93
$32.80
Intervallo di 1 settimana:
$28.87
$32.80
Portata 52W:
$10.60
$32.80
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Nome
Edgewise Therapeutics Inc
Settore
Industria
Telefono
720-262-7002
Indirizzo
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
31.94 | 3.29B | 0 | -167.80M | -144.07M | -1.6323 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-25 | Iniziato | Goldman | Neutral |
| 2025-07-30 | Iniziato | Raymond James | Strong Buy |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-04-30 | Iniziato | Guggenheim | Buy |
| 2025-04-02 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-01-22 | Iniziato | Stifel | Hold |
| 2024-11-22 | Iniziato | Evercore ISI | Outperform |
| 2024-03-07 | Iniziato | Piper Sandler | Overweight |
| 2023-05-01 | Iniziato | Truist | Buy |
| 2022-08-25 | Downgrade | Goldman | Neutral → Sell |
| 2022-04-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-01-28 | Iniziato | Goldman | Neutral |
Mostra tutto
Edgewise Therapeutics Inc Borsa (EWTX) Ultime notizie
Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 12-Month HighHere's Why - MarketBeat
Edgewise Therapeutics stock reaches 52-week high at $31.86 - Investing.com
A Look At Edgewise Therapeutics (EWTX) Valuation After Promising Sevasemten Becker Muscular Dystrophy Data - Sahm
Edgewise Therapeutics team to attend 2026 American College of Cardiology annual meeting - Traders Union
Why Edgewise Therapeutics Stock Topped the Market on Tuesday - AOL.com
Trading Recap: Can Edgewise Therapeutics Inc keep up with sector leaders2026 Price Targets & Free Community Supported Trade Ideas - baoquankhu1.vn
Why Edgewise Therapeutics stock topped the market on Tuesday - MSN
Inflation Data: What analysts say about Edgewise Therapeutics Inc stock2026 Spike Watch & Stepwise Swing Trade Plans - baoquankhu1.vn
How (EWTX) Movements Inform Risk Allocation Models - Stock Traders Daily
Death Cross: Is Edgewise Therapeutics Inc being accumulated by smart money2026 Action & Verified Short-Term Plans - baoquankhu1.vn
Edgewise Therapeutics Inc (EWTX) Stock Price, Quote, News & History - Benzinga
Why Edgewise Therapeutics Stock Topped the Market on Tuesday - The Motley Fool
JPMorgan Chase & Co. Raises Edgewise Therapeutics (NASDAQ:EWTX) Price Target to $45.00 - MarketBeat
JPMorgan raises Edgewise Therapeutics price target on pipeline outlook By Investing.com - Investing.com Canada
Edgewise Therapeutics' (EWTX) "Outperform" Rating Reiterated at Wedbush - MarketBeat
Is Edgewise Therapeutics Inc being accumulated by smart money2026 Action & Verified Short-Term Plans - baoquankhu1.vn
The $3B Biotech With Two Shots On Goal - Benzinga
Insider Sell: Can Edgewise Therapeutics Inc reach all time highs this yearRate Hike & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Assessing Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term MESA Study Results - Yahoo Finance
Granahan Investment Management Trims Edgewise Therapeutics Holdings - National Today
HighVista Strategies Boosts Edgewise Therapeutics Stake - National Today
Edgewise Therapeutics, Inc. $EWTX Shares Purchased by HighVista Strategies LLC - MarketBeat
First Light Asset Management Reduces Stake in Edgewise Therapeutics - National Today
Granahan Investment Management LLC Trims Stock Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
First Light Asset Management LLC Lowers Stock Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Why Edgewise Therapeutics (EWTX) Is Up 6.4% After Long-Term Sevasemten Becker DataAnd What's Next - Yahoo Finance
Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at Conference - MarketBeat
Edgewise Therapeutics (EWTX) Is Up 6.4% After New Long-Term Becker Data On Sevasemten Trial - simplywall.st
A Look At Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term Sevasemten Becker Data - Sahm
Edgewise reports functional stability in Becker dystrophy trial - Investing.com Nigeria
Integral Health Asset Management Boosts Edgewise Therapeutics Stake - National Today
Integral Health Asset Management LLC Raises Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise’s New EDG-7500 Study Signals Broader Cardiovascular Ambitions - TipRanks
Edgewise Therapeutics Completes Key Renal Study for EDG-7500, Setting Up Next Steps for Investors - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV) and Edgewise Therapeutics (EWTX) - The Globe and Mail
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders - BioSpace
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Integer Holdings (ITGR) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
EWTX: 7500 advances toward Phase III in HCM, with Becker data showing disease stabilization - TradingView
American Century Companies Inc. Buys 312,307 Shares of Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise reports functional stability in Becker dystrophy trial By Investing.com - Investing.com Canada
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up - Finviz
Raymond James reiterates Strong Buy on Edgewise Therapeutics stock after trial data - Investing.com Canada
Truist reiterates Edgewise Therapeutics stock rating on trial data - Investing.com India
Truist reiterates Edgewise Therapeutics stock rating on trial data By Investing.com - Investing.com India
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrat - GuruFocus
Will Edgewise Therapeutics Inc stock recover after earningsPortfolio Return Report & Long-Term Capital Growth Ideas - baoquankhu1.vn
EPS Watch: Will Edgewise Therapeutics Inc stock hit new highs in YEAR2026 Highlights & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Trading Systems Reacting to (EWTX) Volatility - Stock Traders Daily
Edgewise Therapeutics Inc Azioni (EWTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):